Abstract:Background Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance. Although the long noncoding RNA H19 is involved in various stages of tumorigenesis, its role in tamoxifen resistance remains unknown. Here, we assessed the role of H19 in the development of tamoxifen-resistant breast cancer. Methods Quantitative real-time PCR analyzed expression of H19 in tamoxifen-resistant breast cancer tissues. Knockdown of H19 was used to assess the sensitivity to tamoxifen in vitro and in vivo. Both knockdown and overexpression of H19 were used to analyze the status of autophagy. Real-time quantitative methylation-specific polymerase chain reaction, chromatin immunoprecipitation, immunofluorescence, and Western blot were used to explore the tamoxifen resistance mechanism of H19. Results In this study, we observed that the expression of H19 was substantially upregulated in tamoxifen-resistant breast cancer cell line and tumor tissues, and knockdown of H19 enhanced the sensitivity to tamoxifen both in vitro and in vivo. Furthermore, knockdown of H19 significantly inhibited autophagy in MCF7 tamoxifen-resistant (MCF7/TAMR) cells. Conversely, overexpression of H19 promoted autophagy. Interestingly, overexpression of H19 in MCF7 tamoxifen-sensitive cells could recapitulate tamoxifen resistance. Moreover, an increase in methylation in the promoter region of Beclin1 was observed in MCF7/TAMR-shH19 cells. In the double knockdown groups, both shH19+shSAHH and shH19+shDNMT3B rescued the Beclin1 promoter region methylation levels and reactivated autophagy functions. A chromatin immunoprecipitation assay further validated that DNMT3B binds to the Beclin1 promoter region and the knockdown of H19 increases this binding. Conclusions Our findings demonstrate that H19 induces autophagy activation via the H19/SAHH/DNMT3B axis, which could contribute to tamoxifen resistance in breast cancer.

Role of long non-coding RNA H19 in therapy resistance of digestive system cancers

The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers

The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy

Correlation of Long Non-Coding Rna H19 Expression with Cisplatin-Resistance and Clinical Outcome in Lung Adenocarcinoma

Role of LncRNA H19 in tumor progression and treatment

Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors

H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

The double-edged sword of H19 lncRNA: Insights into cancer therapy

Long non-coding RNA H19, a novel therapeutic target for pancreatic cancer

Decreased expression of H19/miR-675 ameliorates hypoxia-induced oxaliplatin resistance in colorectal cancer

Progress of long noncoding RNAs in anti-tumor resistance.

Long Noncoding RNA H19: A Novel Oncogene in Liver Cancer

Long non-coding RNA H19 confers resistance to gefitinib via miR-148b-3p/DDAH1 axis in lung adenocarcinoma

Critical roles of long noncoding RNA H19 in cancer

Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer

The Roles of Lncrnas in the Development of Drug Resistance of Oral Cancers

The role of H19 lncRNA in conferring chemoresistance in cancer cells

Role of Non-Coding RNAs and RNA Modifiers in Cancer Therapy Resistance.

H19 Mediates Methotrexate Resistance in Colorectal Cancer Through Activating Wnt/β-catenin Pathway

Long non-coding RNA H19 and cancer: A competing endogenous RNA